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ABSTRACT

CHARLIE WORTH: AMELIORATIVE EFFECTS OF MINOR CANNABINOIDS
OVER HIV-1 TAT-MEDIATED VISCERAL PAIN
(Under the direction of Dr. Jason Paris)

As the total number of people living with HIV continues to rise across the world,
an effective HIV treatment is still sought after. While modern-day advanced therapies
exist for mitigating much of the negative effects of HIV, the virus remains evasive and
problematic in the central nervous system. Thus, even with treatment, many people living
with HIV continue to suffer from a plethora of symptoms. However, a large proportion of
HIV-positive patients claim to feel a reduction in those persevering symptoms after
cannabis usage. This anecdotal evidence has sparked interest in the efficacy of cannabis
constituents for HIV therapy. This investigation first studies the in vitro effects of a
known anti-inflammatory, corticosterone, on human microglial cells that were exposed to
one of the most well-characterized HIV virotoxins, the transactivator of transcription
(Tat). Tat is known to cause significant impairments in central nervous system processes
through several proinflammatory mechanisms, and corticosterone was shown to curtail
these inflammatory effects. In addition, Tat expression was also shown to be correlated
with worsened cognitive functioning in vivo, as seen by poorer performances of mice
expressing Tat in a 5-choice serial reaction time test. Finally, several minor cannabinoids
were shown to reduce peripheral pain in Tat-expressing mice in an acetic acid writhing
assay.

4

TABLE OF CONTENTS

LIST OF FIGURES.......................................................................................................... 6
LIST OF ABBREVIATIONS.......................................................................................... 7
1. INTRODUCTION................................................................................................ 8
2. MATERIALS AND METHODS......................................................................... 13
2.1. SUBJECTS AND HOUSING................................................................. 13
2.2. CHEMICALS……….............................................................................. 13
2.3. CELL CULTURE OF HMC3 HUMAN MICROGLIA...........................14
2.4. IMMUNOCYTOCHEMISTRY AND ASSESSMENT OF
MICROGLIAL ACTIVATION………………………………………….14
2.5.5-CHOICE SERIAL REACTION TIME TEST....................................... 15
2.6. ACETIC ACID WRITHING TEST......................................................... 15
2.7. STATISITICAL ANALYSES…………………………………………..16
3. RESULTS............................................................................................................. 17
3.1. HIV-1 TAT ACTIVATED HUMAN MICROGLIA IN VITRO………..17
3.2. HIV-1 TAT IMPAIRED COGNITIVE FUNCTION IN VIVO………... 17
3.3.HIV-1 TAT PROMOTED VISCERAL PAIN IN MICE THAT WAS
ALLEVIATED BY MINOR CANNABINOIDS………………………..17
4. DISCUSSION....................................................................................................... 23
LIST OF REFERENCES.................................................................................................. 29

5

LIST OF FIGURES

Figure 1

Activation scale examples………………………………………………19

Figure 2

Effects of Tat and varying concentrations of corticosterone on the

activation of HMC3.......................................................................................................... 20
Figure 3

Tat effects on mice nose-pokes in a 5-CSRTT……………………….….21

Figure 4

Total writhes in an acetic acid writhing assay after screening five minor
cannabinoids………………….……………………………………....... .22

6

LIST OF ABBREVIATIONS

cART

Combined Antiretroviral Therapeutics

CB1

Cannabinoid Receptor 1

CB2

Cannabinoid Receptor 2

CBDA

Cannabidiolic Acid

CBDV

Cannabidivarin

CBG

Cannabigerol

CBGA

Cannabigerolic Acid

CBN

Cannabinol

CNS

Central Nervous System

CORT

Corticosterone

DMSO

Dimethyl Sulfoxide

EMEM

Eagle’s Minimum Essential Medium

FBS

Fetal Bovine Serum

HIV

Human Immunodeficiency Virus

HMC3

Human Microglia Cell Line-3

IFNα

Interferon-alpha

IL-

Interleukin

NF-κB

Nuclear Factor-Kappa B

NMDAR

N-Methyl-D-Aspartate Receptor

PLWH

People Living With HIV

RNS

Reactive Nitrogen Species

ROS

Reactive Oxygen Species

Tat

Transactivator of Transcription

TNFα

Tumor Necrosis Factor Alpha

5-CSRTT

5-Choice Serial Reaction Time Test

Δ9-THC

Delta-9-tetrahydrocannabinol

7

1. INTRODUCTION
There is an increasing interest in the suspected ability of cannabinoid usage as a
treatment for medical ailments. One specific area of its potential medical application is its
efficacy in the management of pain associated with a variety of diseases. Of patients
suffering from such diseases, those infected with human immunodeficiency virus (HIV)
are especially noteworthy. As of 2019, there were approximately 38 million people living
with HIV (PLWH) world-wide, with an increase of 1.9 million cases in 2019 alone
(CDC, 2021). The first-line treatment for HIV is combined antiretroviral therapeutics
(cART). While cART are efficacious peripherally, they do not accumulate well in the
central nervous system (CNS) and they cannot eradicate HIV from latent reservoirs
within the body, particularly those in the CNS. This leads to many HIV patients
experiencing neuropathic pain, regardless of current treatment methods.
One particular viral protein that may contribute to the manifestation of several
symptoms present in HIV patients is the HIV-1 transactivator of transcription (Tat),
which has previously been studied with respect to neurocognitive disorders related to
HIV infection. In cell cultures, Tat exerts direct and indirect actions to damage or kill
neurons. Directly, Tat can promote neurotoxicity via actions at the lipoprotein receptorrelated protein, which promotes downstream excitotoxicity via activation of N-methyl-daspartate receptors (NMDARs) (Haughey et al., 2001; Prendergast et al., 2002). Tat can
also activate NMDARs directly along with other cation channels (including voltage-gated
calcium channels and sodium channels) (Haughey et al, 1999; Fitting et al., 2014). Tat
disrupts intracellular processes that buffer these ions, including mitochondrial-mediated
processes that are associated with the generation of reactive oxygen and nitrogen species
(ROS, RNS) (El Amine et al., 2018; Fan & He, 2016). In addition to its direct neurotoxic
8

effects, Tat also exerts indirect neurotoxic actions that are mediated by glial cells. For
instance, astrocytes are important for proper neuronal function given their ability to
buffer ions and neurotransmitters, such as glutamate. Tat impairs the ability for astrocytes
to uptake glutamate, thereby promoting neuronal excitotoxicity (Zhou et al., 2004).
Furthermore, Tat also acts on the immune glial cells of the brain, microglia, by promoting
inflammatory cytokine release that can further damage neurons (El-Hage et al., 2005; Li
et al., 2005; Sheng et al., 2000; Sorrel & Hauser, 2014; Yang et al., 2010). These effects
are also observed in vivo in transgenic mouse models that conditionally-express the HIV1 Tat protein (Bruce-Keller et al., 2008; Holman et al., 2016; Kim et al, 2003; Marks et
al., 2016).
It has been suggested that between 40-74% of HIV patients consume cannabis
(Costiniuk et al., 2019). According to many of cannabis-consuming PLWH, this
cannabinoid use is associated with a reduction in pain, which may identify cannabinoid
usage as a novel potential pain management treatment for patients suffering with
neuropathic pain, particularly those infected with HIV (Dosenovic et al., 2017).
Cannabinoids may even be more desirable than other modern-day pain management
strategies; gabapentinoid or opioid interventions are often prescribed to HIV patients
without successful retraction of pain (Oh et al., 2021). There may also be benefits from
combining cannabis use with established treatment methods (Rasche et al., 2018). Several
studies have indicated smoked cannabis in particular as having analgesic effects on HIVrelated neuropathy; even experimentally induced pain has been shown to be reduced via
smoked cannabis consumption (Lynch & Campbell, 2011). These data often coincide
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with results gathered from surveys and questionnaires given to HIV patients currently
using cannabis (Woolridge et al., 2005; Costiniuk et al., 2019).
The most well-studied constituent of cannabis is delta-9-tetrahydrocannabinol
(Δ9-THC), which acts as a partial agonist at cannabinoid receptors 1 and 2 (CB1 and
CB2, respectively). Notably, activation of these receptors reduces inflammation, while
unmitigated inflammation promotes and sustains pain, particularly neuropathic pain
(Morales et al., 2016). Outside of Δ9-THC, there are over 120 minor cannabinoids in
cannabis that may exert similar effects and, because Δ9-THC is psychoactive, its
therapeutic potential is limited. In large part, psychoactivity is mediated by CB1.
However, CB2 is expressed in immune cells and promotes anti-inflammation, thus minor
cannabinoids that target CB2 would be preferential (Turcotte et al., 2016). Other minor
cannabinoids may act at non-CB sites such as ion channels (i.e. transient receptor
superfamily channels) to reduce pain (Starkus et al., 2019).
Along with neuropathic pain, another common symptom that remains difficult to
treat in PLWH is cachexia, characterized by weight loss and loss of appetite.
Cannabinoids have also been shown to have efficacy in regards to the treatment of this
symptom. Cannabinoids have been observed as being superior to placebo for the outcome
of weight change and appetite in patients suffering from HIV-related cachexia (Mücke et
al., 2016). In particular, dronabinol (a Δ9-THC analogue) has been associated with a
“modest benefit” for HIV-associated weight loss and is currently in use successfully to
increase the appetites of HIV patients suffering from cachexia (Murnion 2015; Croxford
2003). Two hormones responsible for the feelings of hunger and satiety, ghrelin and
leptin, respectively, have been shown to be present in the blood at increased levels upon
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cannabis administration, without causing a significant effect on insulin levels (Riggs et
al., 2012). As with neuropathic pain, cannabinoids have also shown efficacy for
managing HIV-related cachexia when used in conjunction with current advanced HIV
therapies (Rasche et al., 2018). This further suggests cannabinoids may offer relief on
more than one front for HIV patients.
Along with these benefits, cannabinoids have been shown to have a relatively
good safety profile. One common worry about the usage of cannabinoids for medicinal
purposes is abuse liability; however, data suggest that non-psychoactive minor
cannabinoids, such as CBD, exert low potential for abuse (Chayasirisobhon, 2019). Many
different cannabinoids have been studied through various routes of administration, which
has produced an increasingly sizeable body of evidence that supports the claim that the
risk of adverse effects from cannabinoids is generally low and that they are generally
well-tolerated. Data from one survey suggests that the overwhelming majority of
cannabinoid users experience no side effects and claim their cannabis usage leads to
improved symptoms with respect to their illness (Schnelle et al., 1999).
While much of the data regarding the efficacy of cannabinoids seem promising,
there also seems to be some limitations to its usefulness. A meta-analysis suggests that
mental health symptoms may be increased after cannabinoid usage in HIV-patients
(Mücke et al., 2018). Furthermore, there is existing data that suggests high dosages of
cannabinoids may bring about adverse effects or exaggerate pain intensity (Beaulieu &
Ware, 2007). Additionally, a cross-sectional study of HIV-patients that use cannabis
found that nearly half of these users report memory deterioration associated with their
cannabis use (Woolridge et al., 2005).
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In this investigation, we hypothesized that HIV-Tat expression in mice would
impair cognitive function and Tat-mediated inflammation in human microglial cells
would be attenuated with a known anti-inflammatory, corticosterone (CORT).
Additionally, we hypothesized that the algesic effects of Tat would be reversed in Tatexpressing mice with the administration of several different minor cannabinoids.
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2. MATERIALS AND METHODS
The use of mice in these studies was pre-approved by the Institutional Animal
Care and Use Committees at the University of Mississippi. All experiments were
conducted in accordance with ethical guidelines defined by the National Institutes of
Health (NIH Publication No. 85-23).
2.1 - Subjects and Housing
Behavioral studies used adult male and female mice that expressed (or did not) a
GFAP-driven, doxycycline-inducible, HIV-1IIIB tat1-86 transgene (N=8+231; Bruce-Keller
et al., 2008). Female mice were tested only when in the proestrus phase of the estrous
cycle. Tat(-) mice that did not express the tat transgene and Tat(+) mice that did express
the tat transgene were generated in the vivarium at the University of Mississippi. Mice
were young adults (between two and five months) at the time of testing, were housed 35/cage, and were maintained in a temperature- and humidity-controlled room on a 12:12
h light/dark cycle (lights off at 09:00 h) with ad libitum access to food and water.
2.2 - Chemicals
Chemicals used in vitro: Human microglia cell line-3 (HMC3) cells were treated
with vehicle or low-to-high corticosterone (32, 100, 320 nM dissolved in DMSO and
diluted 1:10,000 in media; #27840, Sigma-Aldrich), and vehicle or HIV-1 Tat1-86 (50
ng/mL diluted to concentration in ddH20; #1002-2, ImmunoDx, Woburn, MA). The
chosen Tat concentration was derived from one known to induce functional deficits in
glia and neurons similar to those observed in HIV (El-Hage et al., 2005).
Chemicals used in vivo: Mice were treated with vehicle [10% EtOH, 10%
cremophor, 90% saline (0.9%)] or minor cannabinoids: CBGA, CBDA, CBG, CBN,
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CBDV (10 mg/kg, i.p.; obtained from the Marijuana Research Laboratory, University of
Mississippi, University, MS). To induce HIV-1 tat1-86 transgene expression (or not),
Tat(+) and Tat(-) control mice were administered doxycycline (30 mg/kg, s.c.; #14422,
Cayman Chemical, Ann Arbor, MI) for 5 days with an additional two days of
doxycycline washout prior to behavioral testing (to minimize any potential non-specific
behavioral effects of doxycycline).
2.3 - Cell Culture of HMC3 Human Microglia
HMC3 cells were obtained from ATCC (#CRL2266; Manassas, VA) and
maintained in growth medium: 89.5% EMEM/F12 (Life Technologies, Carlsbad, CA),
10% heat-inactivated fetal bovine serum (FBS; Thermo Scientific Hyclone, Logan, UT),
and 0.5% antibiotic/antimycotic mixture (Life Technologies). For experiments, cells were
seeded onto 24-well plates at a density of 5,000 cells/well. All cells were passaged
between 6 and 12 times. For all experiments, cells were seeded on day 1, underwent
experimental manipulations on day 2 (i.e. treatment with Tat and/or corticosterone), and
were fixed in 4% paraformaldehyde 24 h later.
2.4 - Immunocytochemistry and Assessment of Microglial Activation
Fixed cells were incubated with antibodies against Iba-1 (Wako Pure Chemical
Industries, 019-19741; 1:200) and were visualized following further staining with an antirabbit secondary (AlexaFluor 594; 1:500) and a Hoechst 33342 (1:10,000) nuclear stain.
The total number of cells was counted in each field with at least 25 cells counted per
field. Each condition was represented by two technical replicates per plate and each plate
was considered one observation. All observations were independent experiments.
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To quantify the morphology of HMC3 cells, each cell was scored by a blinded
observer based on the following activation scale: (1) “resting” identified by an elongated
morphology, (2) “activated/reactive” identified by a ramified morphology, or (3)
“phagocytic” identified by an amoeboid morphology (Davis et al., 1994; Yoichi, 1999;
Ladeby, 2005) (Fig 1).
2.5 - 5-Choice Serial Reaction Time Test
Cognitive ability to acquire nose-poke operant responding was assessed in Tat(-)
and Tat(+) mice. Using a 5-choice serial reaction time test (5-CSRTT; Zantiks Ltd.,
Cambridge, UK) mice were trained to nose-poke for a reward of vanilla-flavored
Ensure® (35 µL). Mice were not food-deprived. In brief, mice underwent up to 100 trials
per day for 21 d. Each session began with a free reinforcer. Each trial consisted of the
activation of a house light for 5s, followed by the lighting of 3 of 5 apertures for 20s.
Mice had 20s to nose-poke one of the 3 lit apertures followed by an inter-trial interval of
25 s. The number of correct nose-pokes was calculated as an index of cognitive capacity
to acquire operant behavior.
2.6 - Acetic Acid Writhing Test
Visceral algesia was determined via the acetic acid writhing test (Ross et al.,
2011). In brief, mice were treated with vehicle or minor cannabinoids 30 min prior to
testing. At the time of testing, mice were administered an i.p. injection of acetic acid
(0.7%) and were immediately placed under a clear cylinder. Behavior was recorded for
30 min and scored later by an observer that was blinded to the treatment condition. The
number of writhes per 5 min and the total number of writhes over 30 min were scored.
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2.7 - Statistical Analyses
Microglial activation was assessed via separate two-way ANOVAs (Fig. 2) with
corticosterone condition (0, 32, 100, or 320 nM) and Tat condition (control or Tat 50
ng/mL) as factors. Behavior in the 5-CSRTT was analyzed by day or week via repeated
measures ANOVA with Tat condition [Tat(-) or Tat(+)] as the between-subjects factor
and time (days or weeks) as the within-subjects factor (Fig. 3). Significant differences
following main effects were determined using Fisher’s Protected Least Significant
Difference post-hoc tests. Interactions were delineated via simple main effects and main
effect contrasts with alpha controlled for multiple comparisons. Behavior in the acetic
acid writhing test was assessed via Student’s independent, one-tailed t-tests for each
treatment condition (Fig. 4). All analyses were considered significant when p < 0.05.
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3. RESULTS

3.1 – HIV-1 Tat Activated Human Microglia In Vitro
Exposing human microglial cells (HMC3) to Tat (50 ng/mL) significantly reduced the
proportion of cells that were resting [F(1,181) = 15.29, p < 0.05] (Fig. 2A) and
significantly increased the proportion of cells that were activated in a phagocytic state
[F(1,178) = 37.70, p < 0.05] (Fig. 2B). Tat significantly interacted with a known antiinflammatory, corticosterone, to alter the activation state of microglia [F(3,178) = 3.43, p
< 0.05] (Fig. 2C).
3.2 – HIV-1 Tat Impaired Cognitive Function In Vivo
In a 5-CSRTT, exposure to Tat significantly interacted with performance across the 21
days of testing [F(20,120) = 2.00, p < 0.05] (Fig. 3A). Compared to control, mice
expressing HIV-1 Tat averaged significantly fewer correct nose-pokes per session during
week 1 (p = 0.01), week 2 (p = 0.006), and week 3 (p = 0.03; Fig. 3B). Irrespective of
genotype, the proportion of correct nose-pokes significantly reduced in week 3 compared
to responding in week 1 (p = 0.0003; Fig. 3B).

3.3 - HIV-1 Tat Promoted Visceral Pain in Mice That was Alleviated by Minor
Cannabinoids
In males or females, HIV-1 Tat expression resulted in an increased cumulative number of
writhes in response to acetic acid [tmales(14) = 1.85, p < 0.05; tfemales(18) = 2.28, p < 0.05]
(Fig. 4). In males, pretreatment with the minor cannabinoids CBGA or CBN attenuated
Tat-mediated writhing; whereas, pretreatment with CBG [t(18) = 3.44, p < 0.05], CBDA
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[t(18) = 2.88, p < 0.05], or CBDV [t(18) = 2.44, p < 0.05] did not (Fig. 4). In females,
pretreatment with CBGA, CBG, or CBN attenuated Tat-mediated writhing; but, CBDA
[t(19) = 3.99, p < 0.05] and CBDV [t(17) = 2.64, p < 0.05] did not (Fig. 4).
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Figure 1: Examples of the values assigned to each of the three possible morphologies of
HMC3 cells included in the activation scale.
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2A

2B

2C

Figure 2: Differences in the percent of resting (1A), phagocytic (1B), and mean
activation scale (1C) of HMC3 cells with or without exposure to corticosterone (0, 32,
100, 320 nM) and/or Tat (50 ng/mL). * indicates significant difference from media
control; † indicates significant difference from Tat-exposed control; ‡ indicates
significant difference from respective media-control of the same corticosterone
concentration; p < 0.05.
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3A

3B

Figure 3: Frequency of correct nose-pokes by mice in the 5-CSRTT shown across all 21
days (Fig 3A) and as grouped into three weeks (Fig 3B). ‡ indicates interaction between
Tat expression and time; * indicates significant main effect for Tat(+) to differ from Tat() mice; † indicates significant main effect for week 3 to differ from week 1; p < 0.05.
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Figure 4: Total writhes of Tat(-) or Tat(+) mice in the acetic acid writhing assay after
administration of vehicle or each of the five minor cannabinoids tested separated by sex.
* indicates Tat(+) group significantly differs from respective Tat(-) control administered
the same compound.
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4. DISCUSSION
The hypotheses that HIV-Tat exposure would activate microglia, produce a cognitive
detriment, and augment visceral pain were upheld. The hypothesis that the antiinflammatory, corticosterone, would attenuate Tat-mediated inflammation in human
microglial cells was also upheld and was observed to be concentration-dependent. Lastly,
the hypothesis that potentially anti-inflammatory minor cannabinoids would curtail the
algesic effects of Tat was upheld as well. Together, these data suggest that Tat protein is
sufficient to promote a proinflammatory response that can increase visceral pain and
natural product anti-inflammatories may ameliorate these effects. These data support
prior findings and extend them.
As expected with respect to the current literature, the presence of Tat in HMC3
culture promoted an inflammatory response from the cells, as seen in a significant
increase in the proportion of cells that were characterized by a phagocytic morphology, as
well as a significant decrease in the proportion of cells that assumed a resting
morphology. It should be noted that these two significant observations are not
inextricably linked to one another despite their similarities; in other words, a significant
difference in the proportion of morphologically phagocytic cells does not always
guarantee a significant and opposite difference in the proportions of those that are resting,
and vice versa. The inclusion of the middle ground, “active/reactive” morphology allows
for a transition state to be assessed. The activation scale accounts for all activation states
observed in a culture and we believe provides a more statistically robust outcome.
It is well known that the HIV-1 Tat protein promotes a neuroinflammatory
profile. As shown in the data presented in this study, Tat expression induces microglia to
take on a phagocytic, ameboid morphology, which is characteristically associated with an
23

onset of inflammatory reactions. Specifically, Tat has been shown to interact with the
miRNA-34a-NLRC5-NF-κB signaling axis, ultimately resulting in an up-regulation of
NF-κB, in turn promoting the expression of several proinflammatory cytokines (i.e. IL-1β
and IL-6); this interaction has been studied in vivo on rhesus macaques models
(Periyasamy et al., 2019). This is consistent with prior data that detected a marked
elevation of both cytokines (TNFα, IFNα, IL-7, and IL-10) and chemokines (IP-10,
MCP-1, and MIP-1α) in the cerebrospinal fluid of HIV-positive humans compared to
HIV-negative humans (de Almeida et al., 2016). Additionally, this activated state has also
been referred to as a “senescence-like phenotype,” as an up-regulation in senescence
markers such as p16 and p21 have been previously observed in vitro (Thangaraj et al.,
2021).
Neuroinflammation may contribute to many pathologies among PLWH, including
cognitive dysfunction. A particularly relevant cross-sectional study showed significantly
more cognitive impairment in PLWH when compared to HIV-negative subjects,
regardless of whether or not the PLWH were undergoing treatment with cART (Milanini
et al., 2020). In addition to this, PLWH with fully suppressed HIV RNA (via cART) have
also been shown to have decreased gray matter volume and white matter structural
irregularities (Underwood et al., 2017). White matter irregularities have been proposed to
be an important factor associated with cognitive dysfunction in HIV-infected humans
receiving treatment (Underwood et al., 2017).
There was a marked discrepancy between Tat(+) and Tat(-) mice in their ability to
learn an association between a stimulus (the onset of light) and a reward (Fig. 3A, 3B),
supporting the notion that Tat may impair associative learning. Notably, both groups of
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mice declined in performance by week 3 compared to their performance in week 1. This
is suspected to be due to an enhanced number of correct nose-pokes due to random
chance in the first week. As mice habituate to the task in later weeks, fewer responses
were made, better parsing the groups. In support, the first day of the experiment recorded
the single-highest average correct nose-poke count for the Tat(+) mice.
Natural products that can ameliorate neuroinflammation may improve HIVrelated neurological outcomes. As previously mentioned, the rates of cannabis usage
amongst PLWH may be up to 74%. Along with anecdotal evidence of HIV-related pain
reduction from cannabis ingestion, data from the existing literature also support this
claim. One randomized placebo-controlled study involving PLWH saw a median
reduction of 34% in chronic pain, compared to 17% in the placebo group (Abrams et al.,
2007). The exact constituents of cannabis that might confer anti-inflammatory effects are
not known. However, herein we have found three lead constituents in the current
experiment.
The data from the acetic writhing assay suggests that certain minor cannabinoids
offer a reduction in visceral pain caused by Tat expression. As expected, Tat expression
was associated with an increase in writhes for the vehicle condition in both sexes. In
males, CBGA and CBN administration significantly resulted in less writhes in Tat(+)
mice when compared to Tat(+) mice administered vehicle. Both CBGA and CBN had the
same effect in females, as well as CBG. Although not significant, it is also worth noting
that across both sexes, CBDA appeared to potentially increase writhes. Only five of the
120+ minor cannabinoids were studied, supporting the need for further research into
other minor cannabinoids that may be of interest. Furthermore, the acetic acid writhing
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assay is often used as a way to screen for a compound’s ability to reduce visceral pain;
the effective minor cannabinoids in this study may be potential compounds for study in
more specific modes of pain (e.g. thermal or mechanical pain).
Notably, there were sex differences in the efficacy of some minor cannabinoids
assessed. Though not significant, female mice tended to have more exaggerated
cumulative writhes when compared to males. Also worth noting is that a significant
attenuation of writhes was seen across both sexes after administration of CBGA and
CBN, but CBG only attenuated writhes in females. These findings suggest a potential
sex-determined difference in response to certain minor cannabinoids. Sex differences are
not novel in the realm of Tat’s effects on the brain; male Tat(+) mice have been shown to
down-regulate inhibitory GABAergic synaptic activity, where female Tat(+) mice saw an
up-regulation (Xu et al., 2022). Sex differences have also previously been reported
regarding action of the endocannabinoid system (Cooper & Craft, 2018; Rubino &
Parolaro, 2011). As such, sex-differences should be considered when identifying
cannabinoids that may be efficacious in the treatment of HIV-related pain.
Future studies should seek to extend the data presented in the current work. The
use of primary human microglia may offer a more applicable in vitro model for the study
of Tat on these cells. Many more minor cannabinoids and other cannabis constituents
exist but were not assayed, thus a wide array of compounds may have desirable effects.
More specific pain assays may be used to narrow the exact mechanisms by which these
constituents confer their analgesic properties (i.e. tail-flick test, Hargreaves test, etc).
In conclusion, these data show that Tat expression both in vitro and in vivo can
negatively impact healthy CNS function. Corticosterone, a known anti-inflammatory,
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significantly reversed the HMC3 morphological transition from a resting state to an
activated, pro-inflammatory state. Several minor cannabinoids exert a similarly desirable
effect in mice expressing Tat, as seen in a reduction in visceral pain.
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